Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus

o1853

WEKO3

lat lon distance

[[sub_check.contents]]

[[sub_radio.contents]]

Field does not validate

[[sub_attr.contents]]　

https://fukuoka-u.repo.nii.ac.jp/record/5133/files/o1853.pdf

内容の要旨及び結果の要旨

application/pdf

ファイル	ライセンス
o1853.pdf (534.5 kB) sha256 97854500fae1473d0f2430b590021de490727785389bbcdbd3485d3634316ac7

2020-11-13

Version	Date Modified	Object File Name	File Size	File Hash Value	Contributor Name	Show/非表示

Downloads

Plays